Abstract
Background Bipolar radiofrequency catheter ablation (BRFA) is a potential treatment for refractory ventricular arrhythmias from deep myocardial tissue. However, clear indicators of efficacy and safety remain undefined.
Methods In an ex vivo model, BRFA was performed using either the QDOT Micro™ (QDT) or Thermocool SmartTouch SF™ as the active catheter, with the DiamondTemp Ablation™ (DTA) as the return catheter. Predictors of transmural lesion formation and steam-pop occurrence were assessed.
Results A total of 391 BRFA applications were performed with variations in the interelectrode distance between the active and return catheter tips, ranging from 6 to 27 mm, under various catheter tip and tissue contact configurations. The ablation index (AI) adjusted for inter-electrode distance effectively predicted transmural lesion formation. Logistic regression analysis revealed a coefficient for AI of −0.040 (SE: 0.0067; 95% CI: [−0.053, −0.027]; p < 0.0001) and for inter-electrode distance of 2.2 (SE: 0.35; 95% CI: [1.5, 2.9]; p < 0.0001). The decision boundary for transmural lesion formation was AI = 54 × inter-electrode distance – 260. When AI exceeded this value, sensitivity, specificity, and positive and negative predictive values for predicting transmural lesions were 89%, 92%, 91%, and 90%, respectively. When the AI was further increased by 50, the specificity reached 100%.
Steam-pops on the active catheter side occurred only during power-controlled BRFA and were absent in temperature-controlled BRFA with a 45°C cutoff. On the return side, steam-pops occurred when DTA temperature exceeded 55°C, with deeper cracks observed above 60°C.
Conclusions An AI adjusted for inter-electrode distance strongly predicted transmural lesions. Temperature-controlled BRFA with a 45°C cutoff for QDT as the active catheter and 55°C for DTA as the return catheter may prevent steam-pops. Additionally, steam-pops occurring at higher catheter tip temperatures were associated with deeper tissue cracks.
Clinical Perspective What is known?
Bipolar radiofrequency ablation has shown promise as an effective treatment option for ventricular arrhythmias originating from deep regions of the ventricular myocardium.
The indicators for successful transmural lesion formation and the predictors for steam-pop are not yet well understood, and the accuracy of conventional metrics remains limited.
What the study adds
The ablation index (AI) necessary for achieving successful transmural lesion formation during bipolar radiofrequency ablation, using a QDOT micro™ (QDT) as the active catheter and a DiamondTemp Ablation™ (DTA) the return catheter, can be determined using the formula: AI = 54 × inter-electrode distance – 260, where the inter-electrode distance denotes the distance between the active and return electrodes.
During bipolar radiofrequency ablation, performing temperature-controlled ablation with a temperature cutoff of 45°C for the QDT and 55°C for the DTA may help prevent steam-pop.
Furthermore, the higher the DTA temperature at the time of steam-pop, the deeper the cracks that are formed.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is not a clinical trial
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study uses dead tissue, so IRB review is not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interest: The authors have no conflicts to disclose about this article
Source of funding: none
Data Availability
The datasets generated during the current study are available from the corresponding author upon reasonable request.
